Under the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

Poviztra (semaglutide injection 2.4 mg) is the second brand of Wegovy, Novo Nordisk’s blockbuster obesity medication, which ...

The Indian subsidiary of Danish pharma major Novo Nordisk has partnered with Pune-based Emcure Pharma to expand the reach of ...

Dr. Reddy's Semaglutide weight-loss drug launch in Canada faces delays due to regulatory compliance issues, impacting share ...

CAM2056 showed weight and A1c reductions comparable to or exceeding those seen for weekly semaglutide (Wegovy®) Results include a 9.3% weight reduction with CAM2056 vs. 5.2% with weekly semaglutide at ...

Novo Nordisk India and Emcure Pharma are partnering to introduce Poviztra, a weight-loss medication based on semaglutide, in India. This collaboration aims to enhance accessibility and distribution of ...

Novo Nordisk’s oral semaglutide 25 mg achieved up to 16.6% weight loss in a landmark study, rivaling injectable Wegovy. The ...

As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...